UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

Main Article Content

Patrizia Tosi *
Manuela Imola
Mianulli Anna Maria
Simona Tomassetti
Anna Merli
Annalia Molinari
Serena Mangianti
Marina Ratta
Alessandro Isidori
Giuseppe Visani
(*) Corresponding Author:
Patrizia Tosi | patrizia.tosi@auslrn.net

Abstract

Autologous stem cell transplantation is considered the standard of care for multiple myeloma patients aged < 65 years with no relevant comorbidities. The addition of drugs acting both on bone marrow microenvironment and on neoplastic plasma cells has significantly increased the proportion of patients achieving a complete remission after induction therapy, and these results are mantained after high-dose melphalan, leading to a prolonged disease control. Studies are being carried out in order to evaluate whether short term consolidation or long-term maintenance therapy can result into disease eradication at the molecular level thus increasing also patients survival. The efficacy of these new drugs has raised the issue of deferring the transplant after achivng a second response upon relapse. Another controversial point is the optimal treatment strategy for high-risk patients, that do not benefit from autologous stem cell transplantation and for whom the efficacy of new drugs is still matter of debate.


Downloads month by month

Downloads

Download data is not yet available.

Article Details